Regenxbio’s growth trends
Regenxbio (RGNX) has risen 121.35% YTD (year-to-date). Wall Street analysts expect it to report revenues of $194.55 million in 2018, which is a YoY (year-over-year) rise of 1,772.47%. Regenxbio expects license revenues in the second half of 2018 to be much lower than the first half of 2018 due to the non-recurring nature of those revenues.
In Q2 2018, the company reported revenues of $40 million, which is a YoY rise of 506.1%.
On January 8, Regenxbio entered into an agreement with AveXis, which amended the worldwide licensing agreement the companies entered into in March 2014 related to the development and commercialization of SMA (spinal muscular atrophy) drugs. According to the amendment, the company has received $100 million of accelerated payments from Novartis after the latter completed the acquisition of AveXis.
Regenxbio has received a total consideration of $180 million based on this amended agreement. Regenxbio is also eligible to receive commercial milestone payments of $80 million and milestone payments and royalties on sales of SMA drugs developed by Novartis using Adeno-associated virus (or AAV) vector technology.
Analyst recommendations for Regenxbio
The consensus recommendation for Regenxbio over the next 12 months is a “buy.” Of the six analysts covering Regenxbio in September, four have recommended a “buy,” and two have recommended a “hold.”
Wall Street analysts have projected a 12-month consensus target price for Regenxbio of $87.58, which would be a rise of 18.99% over its closing price on September 13.
At end of June, Regenxbio had $306.3 million of cash on its balance sheet, which was significantly higher than $176.4 million at the end of December 2017. It has projected cash, marketable securities, and cash equivalents on its balance sheet of $250 million–$260 million at the end of December 2018. However, the company has projected cash burn in 2018 of $90 million–$100 million, which is higher than the previous estimate of $85 million–$95 million.
In the next part, we’ll look at the growth trends for Crispr Therapeutics.
Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.